PPARG and renal cell carcinoma: High expression of PPARγ was observed in RCC tissue, while PPARγ agonists (pioglitazone and troglitazone) and the endogenous ligand (15-deoxy-Delta12,14-prostaglandin J(2) (15dPGJ(2)) inhibited human RCC cell proliferation via the stimulation of apoptosis and G0/G1cell cycle arrest [192,193].